Among different factors the presence and activity of multidrug resistance molecules (MDR) are related to failure of anti-cancer therapy. The purpose of this study was analysis of presence of multi-drug resistance proteins such as p-gp, MRP1, LRP and BCRP in childhood Non-Hodgkin’s Lymphomas (NHL) and their association with lymphoma type, immunophenotype of lymphoma cells and therapy results. The expression of multidrug resistance proteins in all studied types of childhood NHL was assayed with immunohistochemistry. The p-gp expression was noted in majority of precursor-cell lymphomas cases, MRP1 and LRP in anaplastic large cell lymphoma cases and BCRP in mature B-cells lymphoma cases. The MRP1 expression in precursor-cell lymphomas was low and did not exceed 40% of cases. A high expression rate (protein found in >75% of lymphoma cells) was noted in most cases in studied NHL types except of MRP1 expression in precursor cell lymphomas. A co-expression of at least two drug resistance proteins was observed in all types of lymphomas. A co-expression of all 4 given proteins was noted in mature B-cells lymphomas and anaplastic large cell lymphomas. The association between expression of given MDR proteins and therapy results showed a statistically significant positive correlation between treatment failure (death) in: mature B cell lymphoma and p-gp, LRP and precursor cell lymphoma and BCRP. Eexpression of MDR proteins was associated with therapy failure in precursor and mature B cell type of lymphoma. In anaplastic large cell lymphoma the high expression of all given MDR proteins seems to be associated with poor therapy results.